|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao H, Huang T and Li H: Risk factors for
skip metastasis and lateral lymph node metastasis of papillary
thyroid cancer. Surgery. 166:55–60. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lim H, Devesa SS, Sosa JA, Check D and
Kitahara CM: Trends in thyroid cancer incidence and mortality in
the United States, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kitahara CM and Sosa JA: The changing
incidence of thyroid cancer. Nat Rev Endocrinol. 12:646–653. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagner M, Khoury H, Bennetts L, Willet J,
Lister J, Berto P, Ehreth J, Badia X, Grimaldi-Bensouda L and
Goetghebeur M: Appraising the value of lenvatinib for radio-iodine
refractory differentiated thyroid cancer (Rr-Dtc): A multi-country
study applying holistic multicriteria decision analysis (Mcda).
Value Health. 18:PA477–PA478. 2015. View Article : Google Scholar
|
|
7
|
Pei ZJ, Zhang ZG, Hu AX, Yang F and Gai Y:
miR-122-5p inhibits tumor cell proliferation and induces apoptosis
by targeting MYC in gastric cancer cells. Pharmazie. 72:344–347.
2017.PubMed/NCBI
|
|
8
|
Xu FF, Xie WF, Zha GQ, Chen HW and Deng L:
MiR-520f promotes cell aggressiveness by regulating fibroblast
growth factor 16 in hepatocellular carcinoma. Oncotarget.
8:109546–109558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang WL, Cao J, Xu B, Yang P, Shen F, Sun
Z, Li WL, Wang Q and Liu F: miR-892a regulated PPP2R2A expression
and promoted cell proliferation of human colorectal cancer cells.
Biomed Pharmacother. 72:119–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsai MM, Wang CS, Tsai CY, Huang CG, Lee
KF, Huang HW, Lin YH, Chi HC, Kuo LM, Lu PH and Lin KH: Circulating
microRNA-196a/b are novel biomarkers associated with metastatic
gastric cancer. Eur J Cancer. 64:137–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gong Y, Wu W, Zou X, Liu F, Wei T and Zhu
J: MiR-26a inhibits thyroid cancer cell proliferation by targeting
ARPP19. Am J Cancer Res. 8:1030–1039. 2018.PubMed/NCBI
|
|
12
|
Sun J, Shi R, Zhao S, Li X, Lu S, Bu H, Ma
X and Su C: E2F8, a direct target of miR-144, promotes papillary
thyroid cancer progression via regulating cell cycle. J Exp Clin
Cancer Res. 36:402017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boufraqech M, Nilubol N, Zhang L, Gara SK,
Sadowski SM, Mehta A, He M, Davis S, Dreiling J, Copland JA, et al:
miR30a inhibits LOX expression and anaplastic thyroid cancer
progression. Cancer Res. 75:367–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sui GQ, Fei D, Guo F, Zhen X, Luo Q, Yin S
and Wang H: MicroRNA-338-3p inhibits thyroid cancer progression
through targeting AKT3. Am J Cancer Res. 7:1177–1187.
2017.PubMed/NCBI
|
|
15
|
Han J, Zhang M, Nie C, Jia J, Wang F, Yu
J, Bi W, Liu B, Sheng R, He G, et al: miR-215 suppresses papillary
thyroid cancer proliferation, migration, and invasion through the
AKT/GSK-3β/Snail signaling by targeting ARFGEF1. Cell Death Dis.
10:1952019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao
H, Li M and Li Y: Down-regulation of miR-218-2 and its host gene
SLIT3 cooperate to promote invasion and progression of thyroid
cancer. J Clin Endocrinol Metab. 98:E1334–E1344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin Y, Hong S, Yu S, Huang Y, Chen S, Liu
Y, Zhang Q, Li Y and Xiao H: MiR-195 inhibits tumor growth and
metastasis in papillary thyroid carcinoma cell lines by targeting
CCND1 and FGF2. Int J Endocrinol. 2017:61804252017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue KC, Hu DD, Zhao L, Li N and Shen HY:
MiR-577 inhibits papillary thyroid carcinoma cell proliferation,
migration and invasion by targeting SphK2. Eur Rev Med Pharmacol
Sci. 21:3794–3800. 2017.PubMed/NCBI
|
|
20
|
Ye Y, Zhuang J, Wang G, He S, Ni J and Xia
W: MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid
carcinoma progression. Oncol Lett. 14:7799–7806. 2017.PubMed/NCBI
|
|
21
|
Sun W, Lan X, Wang Z, Dong W, He L, Zhang
T, Zhang P and Zhang H: MicroRNA-144 inhibits proliferation by
targeting WW domain-containing transcription regulator protein 1 in
papillary thyroid cancer. Oncol Lett. 15:1007–1013. 2018.PubMed/NCBI
|
|
22
|
Lei ST, Shen F, Chen JW, Feng JH, Cai WS,
Shen L, Hu ZW and Xu B: MiR-639 promoted cell proliferation and
cell cycle in human thyroid cancer by suppressing CDKN1A
expression. Biomed Pharmacother. 84:1834–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ferrari N, Ranftl R, Chicherova I, Slaven
ND, Moeendarbary E, Farrugia AJ, Lam M, Semiannikova M, Westergaard
MCW, Tchou J, et al: Dickkopf-3 links HSF1 and YAP/TAZ signalling
to control aggressive behaviours in cancer-associated fibroblasts.
Nat Commun. 10:1302019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou L, Husted H, Moore T, Lu M, Deng D,
Liu Y, Ramachandran V, Arumugam T, Niehrs C, Wang H, et al:
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor
progression and prolongs survival in pancreatic ductal
adenocarcinoma. Sci Transl Med. 10:eaat34872018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katase N, Nishimatsu SI, Yamauchi A,
Yamamura M, Terada K, Itadani M, Okada N, Hassan NMM, Nagatsuka H,
Ikeda T, et al: DKK3 overexpression increases the malignant
properties of head and neck squamous cell carcinoma cells. Oncol
Res. 26:45–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xi M, Cheng L, Hua W, Zhou YL, Gao QL,
Yang JX and Qi SY: MicroRNA-95-3p promoted the development of
prostatic cancer via regulating DKK3 and activating Wnt/β-catenin
pathway. Eur Rev Med Pharmacol Sci. 23:1002–1011. 2019.PubMed/NCBI
|
|
27
|
Xia P and Xu XY: DKK3 attenuates the
cytotoxic effect of natural killer cells on CD133 +
gastric cancer cells. Mol Carcinog. 56:1712–1721. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamzehzadeh L, Caraglia M, Atkin SL and
Sahebkar A: Dickkopf homolog 3 (DKK3): A candidate for detection
and treatment of cancers? J Cell Physiol. 233:4595–4605. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jing L, Gong M, Lu X, Jiang Y, Li H and
Cheng W: LINC01127 promotes the development of ovarian tumors by
regulating the cell cycle. Am J Transl Res. 11:406–417.
2019.PubMed/NCBI
|
|
30
|
Elliott B, Millena AC, Matyunina L, Zhang
M, Zou J, Wang G, Zhang Q, Bowen N, Eaton V, Webb G, et al:
Essential role of JunD in cell proliferation is mediated via MYC
signaling in prostate cancer cells. Cancer Lett. 448:155–167. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu XY, Xia P, Yu M, Nie XC, Yang X, Xing
YN, Liu YP, Takano Y and Zheng HC: The roles of REIC gene and its
encoding product in gastric carcinoma. Cell Cycle. 11:1414–1431.
2012. View
Article : Google Scholar : PubMed/NCBI
|
